logo-loader
viewHumanigen, Inc.

Humanigen presents new study showing lenzilumab's potential to fight tumors

A new study shows the use of lenzilumab in combination with CAR-T therapy for the treatment of leukemia triggers anti-tumor activity

cancerous cells
Lenzilumab is the key drug candidate for the Burlingame, California, company

Humanigen (OTCMKTS:HGEN) this week announced favourable data from a new study evaluating lenzilumab, its flagship therapy, which improves the effectiveness of CAR-T, a new approach to cancer therapy involving altered T cells.

Lenzilumab, the key drug candidate for the Burlingame, California, company is a recombinant monoclonal antibody that neutralizes a substance that promotes growth of white blood cells but is also tied to inflammations that can occur during CAR-T therapies and lead to side effects.

The results of the new study suggest that the use of lenzilumab in combination with CAR-T therapy for the treatment of lymphoblastic leukemia triggered improved anti-tumor activity and  a marked improvement in the control of the leukemia sustained for at least 35 days post CART19 infusion compared to CART19 plus a control.

READ: Humanigen pins hopes on monoclonal antibody treatment of cancer therapy's side effects

The improvement in overall survival rates also came with so-called GM-CSF neutralization, which suggests this factor plays a role in improving CART 19 therapy.

In a statement, Dr. Cameron Durrant, CEO of Humanigen, said: “These results suggest that GM-CSF neutralization would improve the efficacy and toxicity profile of current CAR-T therapies and opens the possibility for other combinations with agents that might further improve efficacy but would be too toxic if used in the absence of GM-CSF neutralization.”

The use of lenzilumab also prevented cases of cytokine release syndrome, which can include fever, nausea, headache, rash, rapid heartbeat, low blood pressure and trouble breathing. It also triggered a reduction in neuroinflammation as well as an increase in CAR-T cell expansion.

READ: Humanigen CEO optimistic on drug candidate after pulling company from the brink

The study was conducted in mice and used human acute lymphoblastic leukemia as well as human-targeted Car-T therapy.

Further phase Ib/II trials of lenzilumab in combination with CART19 therapies are expected to get underway in the coming months.

Humanigen shares closed at $1.35 on Thursday.

Contact Ellen Kelleher: [email protected]

Quick facts: Humanigen, Inc.

Price: 0.35 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $39.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen updates on its clinical collaboration with Gilead Sciences...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco.  Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with...

on 10/23/2019

2 min read